Company intelligence / Profile preview

Etcembly

Harwell, Oxfordshire, United Kingdometcembly.io ↗

Ownership: Private
Employees: ~25
Development stage: Preclinical

Overview

Successfully developed ETC-101, a bispecific T cell engager targeting PRAME with picomolar affinity. The lead drug binds to PRAME with a million-fold greater affinity than a natural TCR without binding to healthy tissue cells, suggesting high potency with few side effects[4][7].

Therapeutic areas: OncologyImmunology
Modalities: T Cell Receptors (TCRs)AntibodiesBispecificsVHHsT cell engagers
Industry: Biotech

Drug pipeline

1 asset

ETC-101

Preclinical

Partnerships

Vector LaboratoriesIlluminaGreat Ormond Street HospitalZelluna ASSingHealthNational Cancer Centre SingaporeImperial College LondonUniversity of Surrey

Beyond the preview

Go deeper on Etcembly.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Etcembly.

Explore the full profile